The USC-developed biomimetic peptide gel is a cutting-edge dental technology designed to regrow and repair superficial tooth enamel. By utilizing amelogenin-derived peptides in a chitosan hydrogel, the product guides the formation of organized hydroxyapatite crystals to remineralize damaged enamel. This non-invasive solution offers a more effective alternative to traditional fluoride treatments by rebuilding underlying structures and restoring enamel hardness. The technology is currently licensed for commercial development.
The biomimetic peptide gel is an advanced dental technology designed to repair and remineralize superficial tooth enamel defects, such as white spot lesions and early-stage erosion. Unlike traditional fluoride treatments that primarily provide a surface patch, this innovation utilizes a synthetically engineered, amelogenin-derived peptide that mimics the natural proteins used by the body to build tooth enamel. By serving as a scaffold, the gel guides calcium and phosphate ions from the oral environment to form organized, hydroxyapatite crystal layers on the tooth surface. This process effectively restores mineral density and improves the mechanical strength of the enamel. The technology offers a non-invasive, pain-free strategy to address enamel degradation, which is a major factor in global oral disease.
The technology has reached a maturity level of 7. After extensive laboratory research, proof-of-concept studies, and successful ex vivo testing, the innovation has been licensed to an industry partner, Verdant Nature Incorporated, which is preparing to bring it to the marketplace as a commercial treatment. The transition from academic research to commercial licensing marks a significant step toward clinical deployment.
USC is a large, comprehensive private research university in Los Angeles, anchored by two urban campuses and an academic health system. Industry engages through applied research institutes such as the Information Sciences Institute, co-located engineering and clinical facilities, and flexible sponsored research contracting. Proximity to the region’s aerospace, media, and biotech corridors provides access to testbeds, talent, and pilot-scale partners across the greater L.A. innovation economy. Research is supported by competitive federal funding from NIH, NSF, and other major agencies alongside significant industry-sponsored awards. A dedicated technology transfer office supports IP strategy, licensing, corporate partnerships, and venture formation.